Program
bemnifosbuvir
Also written as “AT-527”, “Bemnifosbuvir (BEM)” and “AT-527 + digoxin”.
Its studies are mostly in Hepatitis C, Chronic · COVID-19 · Renal Insufficiency, led by 2 companies.
Drug pageBemnifosbuvir: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atea Pharmaceuticalsits history only | 240 open or running | phase 3since Nov 26, 2022 | Jul 13, 2017 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 3since May 10, 2021 | Jan 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jul 13, 2017.
- Jul 28, 2021Named bemnifosbuvirINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AT-527
- Oct 28, 2021Phase 1 study in Healthy Volunteers StudyAtea Pharmaceuticals · NCT05137626 · 29 enrolled · Canada
- Nov 16, 2021Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05154123 · 29 enrolled · Canada
- Feb 16, 2022Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05256732 · 136 enrolled · Canada
- Oct 26, 2022Phase 1 study in Renal InsufficiencyAtea Pharmaceuticals · NCT05618314 · 36 enrolled · Canada
- Nov 26, 2022Phase 3 study in COVID-19Atea Pharmaceuticals · NCT05629962 · 2,285 enrolled · United States, Argentina, Brazil and more
- Jan 24, 2023Phase 1 study in Healthy VolunteerAtea Pharmaceuticals · NCT05724693 · 39 enrolled · United States
- Feb 9, 2023Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05731843 · 32 enrolled · Canada
- Apr 20, 20232 phase 1 studies in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05905497, NCT05905484
- Jun 6, 2023Phase 2 study in Hepatitis C, ChronicAtea Pharmaceuticals · NCT05904470 · 275 enrolled · United States, Brazil, Canada and more
- Jan 2, 2024Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT06204679 · 42 enrolled · United States
- Mar 24, 2025Phase 1 study in Renal InsufficiencyAtea Pharmaceuticals · NCT06911320 · 28 enrolled · United States
- May 19, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07007806 · 20 enrolled · United States
- Nov 19, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07272889 · 24 enrolled · Canada
- Dec 18, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07314346 · 30 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07314346Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Jul 23, 2026 | 30 |
| NCT07272889Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Feb 17, 2026 | 24 |
| NCT07007806Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Jun 28, 2025 | 20 |
| NCT06911320Renal Insufficiency · United States | 1 | Completed | Atea Pharmaceuticals | Apr 30, 2026 | 28 |
| NCT06204679Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Aug 25, 2024 | 42 |
| NCT05904470Hepatitis C, Chronic · United States, Brazil, Canada and more | 2 | Completed | Atea Pharmaceuticals | Dec 9, 2024 | 275 |
| NCT05905497Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | May 19, 2023 | 14 |
| NCT05905484Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | May 31, 2023 | 35 |
| NCT05731843Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Mar 15, 2023 | 32 |
| NCT05724693Healthy Volunteer · United States | 1 | Completed | Atea Pharmaceuticals | Apr 23, 2024 | 39 |
| NCT05629962COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Atea Pharmaceuticals | Apr 25, 2024 | 2,285 |
| NCT05618314Renal Insufficiency · Canada | 1 | Completed | Atea Pharmaceuticals | Jun 15, 2024 | 36 |
| NCT05256732Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Aug 23, 2022 | 136 |
| NCT05154123Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Dec 23, 2021 | 29 |
| NCT05137626Healthy Volunteers Study · Canada | 1 | Completed | Atea Pharmaceuticals | Dec 12, 2021 | 29 |
| NCT05004415Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Aug 12, 2021 | 6 |
| NCT04889040COVID-19 · Argentina, Belgium, Brazil and more | 3 | Terminated | Hoffmann-La Roche | Dec 2, 2021 | 216 |
| NCT04877769Healthy Volunteer Study · United Kingdom | 1 | Completed | Atea Pharmaceuticals | Aug 31, 2021 | 24 |
| NCT04865445Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | May 15, 2021 | 24 |
| NCT04784000Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Apr 10, 2021 | 20 |
| NCT04711187Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Sep 15, 2021 | 81 |
| NCT04709835COVID-19 · Canada, Greece, Ireland and more | 2 | Completed | Hoffmann-La Roche | Sep 17, 2021 | 104 |
| NCT04396106COVID-19 · United States, Argentina, Belgium and more | 2 | Terminated | Atea Pharmaceuticals | Jan 10, 2022 | 83 |
| NCT04309734Hepatitis C · Belgium | 2 | Withdrawn | Atea Pharmaceuticals | Jun 2022 | 0 |
| NCT04019717Hepatitis C · Belgium, Mauritius, Moldova, Republic of | 2 | Completed | Atea Pharmaceuticals | Jan 29, 2020 | 10 |
| NCT03219957Hepatitis C, Chronic · Belgium, Moldova, Republic of | 1 | Completed | Atea Pharmaceuticals | Jun 20, 2018 | 88 |
How it is read
Names in the registry
- “AT-527”, 10 entries
- “Bemnifosbuvir (BEM)”, 4 entries
- “AT-527 + digoxin”, 2 entries
- “AT-527 550 mg + midazolam”, 2 entries
- “Buprenorphine/Naloxone + BEM/RZR”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 4 studies
- COVID-19, 4 studies
- Renal Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.